



8(4): 1-8, 2018; Article no.OR.40049 ISSN: 2321-7227

Keratoconus Plus (KC-Plus): A New Term Proposed by an Egyptian Research Team for Use in Relation to Keratoconus, with Coexisting Cataract

Mohammed Iqbal^{1*}, Ahmed Elmassry², Ahmed Tawfik³, Mervat Elshabrawy Elgharieb⁴, Khaled Nagy⁵ and Waleed Abou Samra⁶

¹Department of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt.
²Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
³Department of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
⁴Department of Ophthalmology, Faculty of Medicine, Suez Canal University, Suez, Egypt.
⁵Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.
⁶Department of Ophthalmology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Authors' contributions

This work was carried out in collaboration between all authors and expert members of the Egyptian Protocol for Keratoconus (EPK) group. Authors MI, AE and AT created and suggested the idea of KC-Plus, created the 3 questionnaire rounds of Delphi-style and prepared for the 3 scientific meetings of the EPK group. Authors AT and MEE designed the study and performed the statistical analysis. Authors MI, KN and WAS wrote the protocol and wrote the first draft of the manuscript. Authors AE and AT managed the analyses of the study. Authors AT and WAS managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/OR/2018/40049 <u>Editor(s):</u> (1) Ahmad M. Mansour, Professor, Department of Ophthalmology, American University of Beirut, Lebanon. <u>Reviewers:</u> (1) Seydi Okumus, Turkey. (2) Bilian Ke, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, China. (3) Ugur Acar, World Eye Hospital, Turkey. Complete Peer review History: <u>http://www.sciencedomain.org/review-history/23696</u>

> Received 2nd January 2018 Accepted 7th March 2018 Published 19th March 2018

Short Communication

ABSTRACT

Purpose: To establish a consensus in the Egyptian literature on the management of keratoconus (KC) and cataract in the same eye.

Methods: An Egyptian research team, including 42 KC experts, met to develop a protocol for the management of KC in Egypt. In three scientific meetings, the Egyptian Protocol for Keratoconus

*Corresponding author: E-mail: dr_m_iqbal@yahoo.com;

(EPK) group focused on the diagnosis and treatment of KC in Egypt. In panels and debates, they discussed procedures to treat coexisting cataract and KC in the same eye. Many experts in the EPK group agreed on the term KC-Plus to refer to KC and cataract in the same eye. The experts then participated in Delphi-style rounds of questionnaires to define this new term.

Results: Thirty-two (76.2%) of the 42 participants who participated in the Delphi-style rounds of questionnaires agreed on the definition of KC-Plus as a term that described the coexistence of cataract and KC in the one eye. The participants agreed on the need for a fourth face-to-face meeting of the EPK group.

Conclusion: Cataract and KC in one eye represent a visual, refractive and corneal dilemma. A solidly designed protocol is needed to guide ophthalmologists in the diagnosis and treatment of patients with coexisting cataract and KC in the same eye. The protocol should address various issues under debate, such as whether the cataract or KC should be treated first. It should also address patient selection, intraocular lens (IOL) selection and optimum biometry formulae. A new term (i.e. KC-Plus) is needed to describe the existence of KC and cataract in the same eye.

Keywords: Keratoconus; CXL-Plus; keratoconus plus; KC-plus; EPK group.

1. INTRODUCTION

Keratoconus (KC) is a non-inflammatory ectatic corneal disease, which is characterized by progressive weakening of the corneal stroma, with apical protrusion. Patients with KC complain of progressive diminution of vision, which necessitates the wearing of frequent spectacles. KC is usually associated with progressive myopia and astigmatism, both of which greatly reduce visual acuity and have a negative impact on vision quality [1,2].

In the last two decades, there have been major advances in operative techniques to treat KC. Prior to these advances, among available procedures, corneal collagen cross-linking (CXL) was the only procedure proven to halt KC progression. All other procedures aimed only to correct the refractive status of the keratoconic eye. The emergence of many new terms in the last decade has made it difficult to draw comparisons between different research outcomes worldwide, with each research team devising its own terminology and abbreviations [1-3].

Recently, Randleman et al. [1] stated the importance of standardizing CXL terminology. They suggested the use of fixed general terms to describe different CXL procedures, thus facilitating comparisons of topographic, refractive and visual outcomes of different research studies worldwide. They recommended the following four terms: CXL, CXL-Plus, prophylactic CXL and PACK-CXL (photo-activated chromophores for keratitis). They proposed the use of the term CXL for the treatment of corneal ectasia and suggested the use of the term CXL-Plus for

therapeutic CXL combined with another refractive procedure. They recommended the use of the term prophylactic CXL for non-ectatic corneas when CXL was used in conjunction with refractive surgery and the use of the term PACK-CXL for the treatment of infectious keratitis. They recommended using the acronyms S-CXL and A-CXL for standard (Dresden protocol) and accelerated CXL, respectively [1,3].

CXL-Plus has two major objectives: CXL aims to halt KC progression, while a refractive procedure is performed to correct the myopic and/or astigmatic components of KC. In CXL-Plus, different procedures are used in conjunction with CXL. These procedures are non-topography guided photorefractive keratectomy (PRK), wavefront guided PRK (WFG PRK), implantation of continuous or segmented intra-corneal ring segments (ICRSs), implantation of a phakic intraocular lens (IOL) and implantation of a toric implantable collamer lens. Implantation of a toric intraocular lens, together with refractive lens surgery, is also used [4-20].

Many researchers have evaluated several IOL power calculation formulas, including SRK, SRK-T and SRKII. They have also evaluated postoperative visual and refractive outcomes, including biometry prediction errors, and the need for post-operative spectacles or rigid gas permeable contact lens. Some researchers have recommended the use of toric IOL implantation in keratoconic eyes and reported that a toric IOL was a good refractive tool to correct refractive outcomes of a keratoconic eye. They also concluded that the grade or stage of KC was vital in surgical decision making regarding each keratoconic eye [10-20]. When treating cataract and KC together, the most important factors that control post-operative visual and refractive results are as follows: IOL formula, IOL selection, patient education (i.e. ensuring that the patient has good understanding of the nature of the disease), the patient's age, counselling of parents of KC patients, grade of KC, stability or progression of KCs and surgical planning (i.e. whether KC or the cataract should be treated first) [10-20].

Two years ago, an Egyptian research team, known as the Egyptian Protocol for Keratoconus (EPK) group, was established to consider the management of KC in conjunction with cataract in the same eye. The EPK group includes professors from many Egyptian universities. The team followed the Delphi method to define a new term to describe KC and cataract in the same eye. Herein, we share the recommendations of the EPK group.

2. METHODS

The team took part in three Delphi-style rounds of questionnaires according to established scientific approaches. The three questionnaire rounds included 12–13 questions of high reliability and validity in each round (Figs. 1, 2 and 3). Forty-two professional KC experts participated in the Delphi method and answered 38 questions in the three rounds. The result of each round was announced to the participants before launching the next round.

In February, March and November 2017, the EPK group attended three major scientific conferences in Luxor and Zagazig Cities in Egypt. These conferences focused mainly on the treatment of KC. At these scientific meetings, several panels and debates discussed in detail issues giving rise to controversies regarding the management of KC in conjunction with cataract. The panel focused on determining the best treatment strategies to manage both cataract and KC with respect to the patient's age, KC grade, final visual acuity and guality outcomes. The panel gave due consideration to patients' professions, expectations and lifestyles. At the second scientific meeting in March 2017 in Luxor, Egypt, the EPK group proposed a new term for KC coexisting with cataract: KC-Plus. Following three Delphi-style rounds of questionnaires, the team will attend a face-toface meeting this year to discuss the results of the Delphi method and to vote on the use of the proposed term (KC-Plus) in Egypt.

Data collected from the corneal experts during the various Delphi-style rounds were collated using Microsoft Excel (Microsoft Office 2010) and analysed using the Statistical Package for the Social Sciences, version 22 (SPSS for Windows).

3. RESULTS AND DISCUSSION

The three scientific meetings yielded many results and recommendations regarding the treatment of KC and cataract in the same eye, including which should be treated first (i.e. KC or the cataract). The main conclusion of these meetings was that surgeons are dealing with an unstable unpredictable refractive situation, which needs to be studied in detail, and that a good surgical plan needs to be put in place for KC-Plus. The most important outcome of the meeting was that 32 (76.2%) of the EPK participants voted to accept the new term KC-Plus to describe the medical condition of cataract consisting with KC. Detailed results will be announced after a fourth face-to-face meeting of the EPK group this summer.

The panel confirmed that the treatment of keratoconic eves presenting with cataract poses a major visual, refractive and corneal dilemma. For example, IOL calculation formulas are not 100% accurate in keratoconic eyes. To improve post-operative visual outcomes, prior to calculation of IOL power in keratoconic corneas, surface corneal irregularities must be treated, and high order aberrations must be decreased. Questions surround the best possible procedures to flatten the corneal surface, eliminate anterior corneal surface irregularities or even customize CXL to treat localized ectatic corneal areas before calculating the IOL power for cataract surgery. Taking into consideration that many young keratoconic patients treated today will be liable to develop senile cataract after the age of 50 years, it may be that KC treatment should take place at a young age to correct anterior corneal surface irregularities and reduce the astigmatic component of KC. If these patients develop cataract in the future, accurate IOL calculations needed for cataract surgery will be easier.

The panel reached a consensus that correcting anterior corneal surface irregularities before cataract surgery is important for both accurate IOL biometry calculations and decreasing the cylinder that needed to be corrected in toric IOL implantation. The panel also reached an

#EPK_KCPLUS_ Delphi	i_ Round 1_Questionnaire
---------------------	--------------------------

Prof Name:			University:
1- In your practice,	the existence of KC	and Cataract to	gether is :
Common	Uncommon	Not rare	Rare
2- Have you ever tre	ated KC with Cata	ract at the same	time ?
Yes		No	
3- Do you prefer usin	ng Toric IOLs in ti	reating Cataract	in Keratoconic patients ?
Yes		No	
4- In managing KC treating :	with Cataract, if P	K / DALK not in	dicated, I prefer to start
КС		Cataract	
5- Do you agree that children ?	our priorities in tr	reating KC with	Cataract vary in adults from
Yes		No	
6- Do you agree that difficulty in IOL of		anaging KC witl	n Cataract arises from the
Yes		No	
7- Do you agree that with Cataract ?	there is no one per	rfect formula for	IOL power calculation in KC
Yes		No	
8- Do you agree that	we should flatten	the cornea befor	e measuring IOL power ?
Yes		No	
9- Do you agree that	ICRS implantatio	n is necessary be	fore measuring IOL power ?
Yes	No		May be
10- Do you agree that	the coexistence of	KC with Catara	ct is an interesting condition ?
Yes	No		May be
11-Did you notice that	at all previous 10 q	uestions include	I KC with Cataract ?
Yes		No	
•	we should use a sp		scribe KC with Cataract ?
Yes		No	
13- Do you agree to us with Cataract ?	se the new term KO	C PLUS from the	EPK GROUP to describe KC
Yes		No	

Signature

Fig. 1. Delphi method round 1

agreement that WFG PRK or custom PRK was an ideal operative tool to correct anterior corneal surface irregularities and minimize high order aberrations. They concluded that these steps can improve the anterior corneal surface, with a much lower cylinder, thereby allowing more accurate IOL power calculations and improved post-operative visual quality outcomes. Most of the panelists accepted that it was necessary to flatten the anterior corneal surface using ICRSs, mainly the segmented type. Some KC specialists on the panel refused the idea of implanting ICRS prior to cataract surgery. They preferred WFG PRK over segmented ICRS and claimed that ICRS would adversely affect postoperative corneal refractive stability and definitely have a negative impact on cataract surgery, long-term refractive outcomes and vision quality outcomes in the long term. Corneal experts who refuted the idea of implanting ICRS before cataract surgery stressed that allergic conjunctivitis is common in Egypt, especially in rural regions. Chronic eye rubbing is a major contributor to distorting the stability of the ICRS within the corneal stoma. In severe cases, it can culminate in ICRS explanation. If this happens after the IOL had been implanted, recorrecting the refractive and corneal dilemma will be a major challenge. The aforementioned factors explain why some panelists were not in favour of the inclusion of ICRS as part of the therapeutic plan in KC-Plus.

#EPK_KCPLUS_ Delphi_ Round 2_Questionnaire

Prof Name:

University:

	operated a cataract case and then postoperatively you discovered the patient had undiagnosed KC ?
Yes	No
prefer to treat I	s prefer start treating cataract first before KC, while other colleagues KC first before cataract. In a cataract case with KC with 51/56 D Ks, lest location, you prefer start treating : Cataract
	s example, do you agree that we can never accurately calculate the less we flatten the cornea first ?
Yes	No
cornea and we	s example, do you agree that CXL alone is not enough to flatten the need ICRS implantation ?
Yes	No
	at the recent advances in KC diagnostic tools have increased the rate of the last decade ?
Yes	No
	at the number of patients that received KC treatment in the last decade nore than the previous decades ?
Yes	No
7- Do you agree th	at most of these patients are teens and twenties ?
Yes	No
	at even the highly specialized KC surgeons are not alike regarding their ol management strategies ?
Yes	No
9- Do you agree th are treating nov	at one day senile cataract will affect most of keratoconic eyes that you v ?
Yes	No
	at most of KC patients treated in the last decade will need further rence for senile cataract in the next 3-4 decades ?
Yes	No
	at with the new 1 in 375 population KC prevalence we should expect resented with both KC and cataract in the future ?
Yes	No
the existence of	at we have to design a special protocol using a specific term, describing KC with cataract, regarding how can we treat cataract in already fully, er treated KC patients ?
Yes	No

Signature

Fig. 2. Delphi method round 2

Prof Name:	University:
1- In adults presenting with KC and ca	
KC	Cataract
2- If you started treatment of KC in a	dults before cataract, do you agree that CXL
is mandatory ?	
Yes	No
	dults before cataract, what is your sharp K2
	ith CXL to flatten the cornea before cataract
48 D 49 D 50 D 5	
	dults before cataract, what is your sharp
astigmatic reading that makes you object to before cataract ?	do ICRS with CXL to flatten the cornea
3 D 4 D	5 D >6 D
	dults before cataract, do you agree that CXL
alone is enough before cataract if K	
Yes	No
6- In the previous example (No 5), do ye	ou agree that CXL alone is enough because toric
IOL is sufficient to correct the cornea	
Yes	No
	l visually SIGNIFICANT cataract, you prefer
to start treating:	
KC	Cataract
KC	Cataract
8- In the previous example (No 7) and it	f you choose to start treating cataract first, do
8- In the previous example (No 7) and it	
8- In the previous example (No 7) and in you agree to leave the eye aphakic the Yes	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is thunilateral visually SIGNIFICANT of the second sec	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ?
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ?
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No 1 visually INSIGNIFICANT cataract, you
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No t visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 12- In the previous example (No 10) and you agree to leave the eye aphakic the eye aphaki	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No if you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is the unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 12- In the previous example (No 10) and the previous exa	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No if you choose to start treating cataract first, do
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is th unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 12- In the previous example (No 10) and you agree to leave the eye aphakic the Yes 13- In adults with KC and cataract required the set of the set	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No if you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No ring DALK/PKP, do you agree that it's better to
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is th unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 12- In the previous example (No 10) and you agree to leave the eye aphakic the Yes 13- In adults with KC and cataract requir leave the eye aphakic and then to do 2 	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No if you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No ring DALK/PKP, do you agree that it's better to cry IOL implantation later ?
 8- In the previous example (No 7) and it you agree to leave the eye aphakic the Yes 9- In the previous example (No 7), is th unilateral visually SIGNIFICANT of Yes 10- In children presenting with KC and prefer to start treating: KC 11- In the previous example (No 10) and agree that we deal in this situation like Yes 12- In the previous example (No 10) and you agree to leave the eye aphakic the Yes 13- In adults with KC and cataract required the set of the set	f you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No he answer "Yes" in (No 8) applicable for cataract with KC ? No I visually INSIGNIFICANT cataract, you Cataract if you choose to start treating KC first, do you e adults ? No if you choose to start treating cataract first, do n to treat KC followed by 2ry IOL implantation No ring DALK/PKP, do you agree that it's better to

#EPK_KCPLUS_Delphi_Round 3_Questionnaire

Fig. 3. Delphi method round 3

All the panelists reached a consensus that corneal CXL is mandatory for all keratoconic eyes up to the age of 30 years. However, there was great debate among the panelists as to whether S-CXL or A-CXL should be selected. There was also a major debate about whether WFG PRK and CXL (CXL-Plus) should be performed simultaneously or sequentially. The panelists agreed that refractive correction in KC-Plus is multifactorial. They stated that visual rehabilitation includes both corneal and lens levels. The panelists also confirmed the importance of correcting the highest possible cylinder dioptric power at the corneal level, thus facilitating correction of the remaining cylinder dioptric power by toric IOL. The need for further

Iqbal et al.; OR, 8(4): 1-8, 2018; Article no.OR.40049

post-operative optical rehabilitation following both corneal and lens surgeries was considered optional. The panel reached a consensus that additional optical correction could be undertaken to improve both acuity and quality of vision. They added that a variety of optical aids, such as spectacles, soft conventional or toric contact lenses, rigid gas permeable contact lenses and scleral contact lenses, could be used.

4. CONCLUSION

The final results of the Delphi rounds regarding the Egyptian consensus on the proposed term KC-Plus and outcomes of the fourth face-to-face meeting of the EPK group scheduled to take place this summer will be published later.

CONSENT

As per international standard or university standard written patient consent has been collected and preserved by the authors.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

The authors acknowledge the sincere help and support of Mr. Ahmed Saber and Mr. Mostafa Saber in assisting and preparing this manuscript.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- 1. Randleman JB, Khandelwal SS, Hafezi F. Corneal cross-linking. Surv Ophthalmol. 2015;60:509-523.
- Kamiya K, Ishii R, Shimizu S, et al. Evaluation of corneal elevation, pachymetry and keratometry in keratoconic eyes with respect to the stage of Amsler-Krumeich classification. Br J Ophthalmol. 2014;98:459-63.
- Randleman JB, Santhiago M, Hafezi F, et al. Corneal Cross-Linking (CXL): Standardizing terminology and protocol nomenclature. Journal of Refractive Surgery. 2017;33(11):727-9.

- Kymionis GD. Corneal collagen cross linking – PLUS. Open Ophthalmol J. 2011;5:10.
- 5. Aiello F, Nasser J, Nucci C, et al. Cataract surgery in patients with keratoconus: Pearls and pitfalls. Open Ophthalmol J. 2017;11:194–200.
- Iqbal M, Hosam A. Ibrahim Elzembely, Mortada Ahmed AboZaid, et al. Three-year outcomes of cross-linking PLUS (combined cross-linking with femtosecond laser intracorneal ring segments implantation) for management of keratoconus. Journal of Ophthalmology. 2018;8. Article ID: 6907573.

DOI: 10.1155/2018/6907573

- Oie Y, Kamei M, Matsumura N, Fujimoto H, Soma T, Koh S, Tsujikawa M, Maeda N, Nishida K. Rigid gas-permeable contact lens-assisted cataract surgery in patients with severe keratoconus. J. Cataract Refract. Surg. 2014;40(3):345–348.
- Ibrahim O, Elmassry A, Said A, et al. Combined femtosecond laser-assisted intracorneal ring segment implantation and corneal collagen cross-linking for correction of keratoconus. Clin Ophthalmol. 2016;10:521-6.
- Nanavaty MA, Lake DB, Daya SM. Outcomes of pseudophakic toric intraocular lens implantation in keratoconic eyes with cataract. J. Refractive Surg (Thorofare, NJ: 1995). 2012;28(12):884– 889.
- Kymionis GD, Grentzelos MA, Portaliou DM, et al. Corneal collagen cross-linking (CXL) combined with refractive procedures for the treatment of corneal ectatic disorders: CXL-Plus. J Refract Surg. 2014;30:566-76.
- 11. Bozorg S, Pineda R. Cataract and keratoconus: Minimizing complications in intraocular lens calculations. Semin. Ophthalmol. 2014;29(5-6):376–379.
- Kontadakis GA, Kankariya VP, Tsoulnaras K, et al. Long-term comparison of simultaneous topography-guided photorefractive keratectomy followed by corneal cross-linking versus corneal cross-linking alone. Ophthalmology. 2016;123(5):974-83.
- Hashemi H, Heidarian S, Seyedian MA, Yekta A, Khabazkhoob M. Evaluation of the results of using Toric IOL in the cataract surgery of keratoconus patients. Eye Contact Lens. 2015;41(6):354–358.

Iqbal et al.; OR, 8(4): 1-8, 2018; Article no.OR.40049

- Coskunseven E, Sharma DP, Grentzelos MA, et al. Four-stage procedure for keratoconus: ICRS implantation, corneal cross-linking, toric phakic intraocular lens implantation, and topography-guided photorefractive keratectomy. J Refract Surg. 2017;33(10):683-689.
- Leccisotti A. Refractive lens exchange in keratoconus. J. Cataract Refract. Surg. 2006;32(5):742–746.
- Lee H, Kang DSY, Ha BJ, et al. Visual rehabilitation in moderate keratoconus: Combined corneal wavefront-guided transepithelial photorefractive keratectomy and high-fluence accelerated corneal collagen cross-linking after intracorneal ring segment implantation. BMC Ophthalmol. 2017;17(1):270.
- Watson MP, Anand S, Bhogal M, Gore D, Moriyama A, Pullum K, Hau S, Tuft SJ. Cataract surgery outcome in eyes with keratoconus. Br. J. Ophthalmol. 2014;98(3):361–364.
- Thebpatiphat N, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Cataract surgery in keratoconus. Eye Contact Lens. 2007;33(5):244–246.
- Cua IY, Qazi MA, Lee SF, Pepose JS. Intraocular lens calculations in patients with corneal scarring and irregular astigmatism. J. Cataract Refract. Surg. 2003;29(7):1352–1357.
- 20. Moshirfar M, Walker D, Birdsong C. Cataract surgery in eyes with keratoconus: A review of the current literature. Curr Opin Ophthalmol. 2018;29(1):75-80.

© 2018 lqbal et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: http://www.sciencedomain.org/review-history/23696